Goa-based medtech firm Molbio Diagnostics has acquired a 70% stake in Bengaluru-based Prognosys Medical Systems, a renowned manufacturer of the Prorad range of Digital X-Ray units and C-arms and developer of a comprehensive digital health platform.

Prognosys builds radiology and fluoroscopy solutions under the brand name PRORAD at its facility based out of Bengaluru that complies with national and international regulatory requirements.

The recent introduction of the unique PRORAD Portable and Ultra-Portable digital x-ray units manufactured, for the first time in India, by Prognosys, can deliver high-quality chest images combined with Artificial Intelligence (AI) driven algorithms for automated interpreting and reporting at the point of care.

The combination of PRORAD and Truenat system offers a game-changing solution for screening and confirming large populations for highly contagious and devastating diseases such as tuberculosis (TB), COVID-19 and other chest anomalies.

This technology will be offered alongside Molbio’s patented Truenat technology, a point-of-care, portable, battery-operated Real-Time PCR platform that can screen over 40 diseases with a sample-to-result time of 60 minutes. Hailed globally as a high-impact breakthrough innovation, Truenat is the world’s first point-of-care molecular diagnostic platform endorsed by the World Health Organisation (WHO) and approved by the Indian Council of Medical Research (ICMR) for TB detection and COVID-19 testing.

Molbio and Prognosys are already working together on mobile solutions for end-to-end screening and diagnosis of MTB and E-Clinics for delivering comprehensive healthcare to the last mile.